| Target | Type of antigen | HLA | Immunization | Binding Assay | In Vitro Function Verification | Epitope Identification | Specificity Verification | In Vivo Function evalsuation | Safety evalsuation |
| MAGEA4/8 | CTA | HLA-A2.1 |
|
||||||
| PRAME | CTA | HLA-A2.1 |
|
||||||
| PRAME | CTA | HLA-A24.2 |
|
||||||
| NY-ESO-1 | CTA | HLA-A2.1 |
|
||||||
| MAGEA1 | CTA | HLA-A2.1 |
|
||||||
| MAGEA10 | CTA | HLA-A2.1 |
|
||||||
| KRAS G12V | Neoantigen | HLA-A11.1 |
|
||||||
| KRAS G12D | Neoantigen | HLA-A11.1 |
|
||||||
| HPV16 E7 | Virus | HLA-A2.1 |
|
||||||
CTA：癌睾抗原
